GlassScriptPhysician profile
Stephen R Coleman
NPI 1992790265
$1,529.65
in general payments reported to CMS, 2019-2025
22 companies · $300 in 2025
The $300 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $89.48 · 2022: $74.24 · 2023: $182 · 2024: $248 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $339.23 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $214.35 | 2019-2020 | |
| Sanofi Pasteur INC. | $163.79 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $127.82 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaqta |
| Cranial Technologies, INC | $105.11 | 2019-2025 | Doc Band |
| Corium, LLC | $68.20 | 2023-2025 | Azstarys |
| Adlon Therapeutics L.P. | $62.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $55.88 | 2023-2024 | Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $51.76 | 2022-2025 | Bexsero, Boostrix |
| Collegium Pharmaceutical, INC. | $51.14 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $42.39 | 2024-2025 | |
| Pfizer INC. | $39.61 | 2019-2024 | |
| Boston Scientific Corporation | $29.03 | 2025 | Artisan |
| Alk-Abello, INC | $24.40 | 2025 | Neffy |
| Kaleo, INC. | $23.72 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $23.64 | 2019 | |
| Verrica Pharmaceuticals INC. | $23.38 | 2024 | Ycanth |
| Rhythm Pharmaceuticals, INC. | $19.32 | 2025 | Imcivree |
| Smith+Nephew, INC. | $17.48 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.21 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.67 | 2024 | Qelbree |
| Ultragenyx Pharmaceutical INC. | $14.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.